FMC continues to face crop protection destocking pressure with generic competition eroding diamides franchise margins. Channel inventory normalization has taken longer than guided. Biologicals segment growth helpful but not enough to offset legacy headwinds. Patent expirations on key products tighten the medium-term outlook.
Signals scoped to US · Company-specific tagging coming soon.